La terapia peptidica, decodificata.
oltre 200 monografie cliniche, calcolatori di dosaggio interattivi e recensioni della comunità - tutte con riferimento a PubMed e di libero accesso.
Che cosa sta cercando?
Longevità e salute della pelle
Crescita muscolareIpertrofia e forza
Perdita di grassoMetabolismo e composizione corporea
CognitivoConcentrazione e neuroprotezione
RecuperoGuarigione e riparazione delle lesioni
DormireQualità e ritmo circadiano
ImmunitàDifesa e resilienza
Salute sessualeLibido ed equilibrio ormonale
Ultime ricerche e formazione
Peptide Angio-3 Attenuates Pulmonary Fibrosis Via Modulation of Coagulation Factor Xa-PAR-1 Signaling Axis
Angio-3, a 10-residue peptide derived from human plasminogen kringle 3, demonstrated significant antifibrotic activity in pulmonary fibrosis models by functioning as a PAR-1 antagonist that disrupts the coagulation factor Xa-PAR-1 signaling axis. The peptide inhibited fibroblast invasion and migration with a favorable safety profile—no adverse effects at 0.5 mg/kg/day and only mild hepatomegaly at supratherapeutic doses.
Living Meta-Analysis Finds No Clear Pancreatitis Signal for Semaglutide and Tirzepatide in Randomized Trials
A living systematic review of placebo-controlled RCTs through March 2026 finds no statistically significant increase in acute pancreatitis risk with semaglutide or tirzepatide, though event rates remain low and continued surveillance is warranted.
Semaglutide Cuts Cardiovascular Events by 21% in Patients at High Risk of Liver Fibrosis: SELECT Subanalysis
A prespecified subanalysis of the SELECT trial shows semaglutide 2.4 mg weekly reduces MACE by 21% in patients with obesity, cardiovascular disease, and elevated fibrosis risk markers — suggesting dual cardioprotective and hepatoprotective benefit.
NPR1 Agonist Antibody XXB750 Paradoxically Worsens Heart Failure in Phase 2 Trial
Novartis's XXB750, a monoclonal antibody designed to activate natriuretic peptide receptor 1, unexpectedly increased NT-proBNP, lowered cGMP, and caused more worsening heart failure events than placebo — suggesting it behaves as a functional antagonist of endogenous natriuretic peptides.
AMG 133 Combines GIPR Antagonism With GLP-1 Agonism in a Single Monthly Injection for Obesity
Amgen scientists report the design of AMG 133 (maridebart cafraglutide), an antibody-peptide conjugate that pairs GIPR antagonism with GLP-1R agonism, producing sustained weight loss in preclinical models and now advancing through Phase III trials with potential once-monthly dosing.
Antimicrobial Peptide WK-13-3D Provides Complete Protection Against Japanese Encephalitis Virus in Mice
A synthetic LL-37 analogue peptide, WK-13-3D, demonstrated potent antiviral activity against Japanese encephalitis virus by binding directly to viral particles and blocking cell entry, achieving 100% survival in pre-treated mice versus 17% in controls.
Calcolatori e strumenti clinici
Calcolatore di ricostituzione
Calcolo delle unità di siringa e del dosaggio dei peptidi liofilizzati
Provate →⚖️Calcolatore del dosaggio del peso corporeo
Calcolo della dose in base al peso del paziente e ai protocolli mcg/kg
Provate →⏱️Calcolatore dell'intervallo di emivita e di dosaggio
Stima dello stato stazionario, degli intervalli di dosaggio e delle finestre di clearance
Provate →🔄Convertitore di unità peptidiche
Convertire tra microgrammi, milligrammi, UI e unità di siringa
Provate →Esperienze reali di utenti realiNUOVO
Game-changer for my knee recovery
After 6 weeks of subcutaneous injections, the chronic tendon pain I'd had for 2 years was down to almost nothing. Combined with PT, the results were remarkable.
Utente verificato · 8 settimane
Steady weight loss, minimal sides
Lost 14 lbs over 3 months on the titration schedule. Nausea was real the first 2 weeks but manageable. Worth it for the appetite control alone.
Utente verificato · 12 settimane
Best GH stack I've tried
Noticeably better sleep by week 2, improved recovery from training by week 4. Skin quality improved. No water retention like with GHRP-6.
Utente verificato · 16 settimane
Latest Peptide News
STAT News Investigation: How Thin Science Fuels the Peptide Hype Machine
STAT News · 6 apr
FDA Expected to Lift Restrictions on 14 Peptides Under RFK Jr. Push
Reuters · 4 apr
FDA Approves Foundayo (Orforglipron): First Oral GLP-1 for Obesity
FDA · 3 apr
Novo Nordisk Announces $12B Manufacturing Expansion for GLP-1 Drugs
Bloomberg · 2 apr
Eli Lilly Tirzepatide Receives Pediatric Approval for Adolescent Obesity
Reuters · 1 apr
Monografie
Strumenti interattivi
Le lingue
Indipendente